Pemigatinib in Treating Patients With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Rearrangement

Study Overview
=================
Brief Summary
-----------------
This is a phase 2 study to investigate the efficacy and safety of Pemigatinib in treating patients with advanced/metastatic or surgically unresectable cholangiocarcinoma with FGFR2 rearrangement who have failed at least 1 previous therapy

Official Title
-----------------
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Rearrangement Who Failed at Least One Previous Therapy

Conditions
-----------------
Cholangiocarcinoma

Intervention / Treatment
-----------------
* Drug: Pemigatinib


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Men and women, aged 18 or older. Histologically or cytologically confirmed cholangiocarcinoma which was considered to be advanced/metastatic or surgically unresectable by the investigator through image examination. Radiographically measurable disease per RECIST v 1.1 Documentation of FGFR2 rearrangement. Documented disease progression after at least 1 line of prior systemic therapy. ECOG performance status of 0 1. Life expectancy ≥12 weeks. Exclusion Criteria: Prior receipt of a selective FGFR inhibitor. History of calcium and phosphate hemostasis disorder or systemic mineral imbalance with ectopic calcification of softy tissues ( exception: skin, kidney, tendons or vessels due to injury, disease, and aging, in the absence of systemic mineral imbalance). Currently evidence of clinically significant corneal or retinal disorder confirmed by ophthalmologic examination. Use of any potent CYP3A4 inhibitors or inducers within 14 days or 5 half-lives, whichever is shorter, before the first dose of study drug. Topical ketoconazole will be allowed.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Pemigatinib in patients with advanced/metastatic or surgically<br>Patients with advanced/metastatic or surgically unresectable cholangiocarcinoma | Drug: Pemigatinib<br>* Pemigatinib will be self-administered at 9mg Or 13.5mg as a QD oral treatment on a 2-week-on therapy and 1-week-off therapy schedule<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Objective response rate per RECIST 1.1 |  | Every 6 weeks for the first 2 cycles and every 9 weeks thereafter through end of treatment, up to 24 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| PFS（PFS= first dose to progressive disease or death） |  | Time from first treatment to the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months | 
| DOR（DOR= time from the date of CR or PR until PD） |  | Every 6 weeks for the first 2 cycles and every 9 weeks thereafter through end of treatment, up to 24 months | 
| DCR（DCR=CR + PR + stable disease） |  | Every 6 weeks for the first 2 cycles and every 9 weeks thereafter through end of treatment, up to 24 months | 
| OS（OS= first dose to death of any cause） |  | Time from first treatment to the date of death from any cause, up to 24 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
CCA, FGFR2, Pemigatinib